Premium
Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts
Author(s) -
Lange Jane M.,
Laviana Aaron A.,
Penson David F.,
Lin Daniel W.,
BillAxelson Anna,
Carlsson Sigrid V.,
Newcomb Lisa F.,
Trock Bruce J.,
Carter H. Ballentine,
Carroll Peter R.,
Cooperberg Mathew R.,
Cowan Janet E.,
Klotz Laurence H.,
Etzioni Ruth B.
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32557
Subject(s) - medicine , prostate cancer , watchful waiting , metastasis , cohort , cancer , prostate , oncology , prostate biopsy , biopsy
Background Active surveillance (AS) is an accepted means of managing low‐risk prostate cancer. Because of the rarity of downstream events, data from existing AS cohorts cannot yet address how differences in surveillance intensity affect metastasis and mortality. This study projected the comparative benefits of different AS schedules in men diagnosed with prostate cancer who had Gleason score (GS) ≤6 disease and risk profiles similar to those in North American AS cohorts. Methods Times of GS upgrading were simulated based on AS data from the University of Toronto, Johns Hopkins University, the University of California at San Francisco, and the Canary Pass Active Surveillance Cohort. Times to metastasis and prostate cancer death, informed by models from the Scandinavian Prostate Cancer Group 4 trial, were projected under biopsy surveillance schedules ranging from watchful waiting to annual biopsies. Outcomes included the risk of metastasis, the risk of death, remaining life‐years (LYs), and quality‐adjusted LYs. Results Compared with watchful waiting, AS biopsies reduced the risk of prostate cancer metastasis and prostate cancer death at 20 years by 1.4% to 3.3% and 1.0% to 2.4%, respectively; and 5‐year biopsies reduced the risk of metastasis and prostate cancer death by 1.0% to 2.4% and 0.6% to 1.6%, respectively. There was little difference between annual and 5‐year biopsy schedules in terms of LYs (range of differences, 0.04‐0.16 LYs) and quality‐adjusted LYs (range of differences, −0.02 to 0.09 quality‐adjusted LYs). Conclusions Among men diagnosed with GS ≤6 prostate cancer, obtaining a biopsy every 3 or 4 years appears to be an acceptable alternative to more frequent biopsies. Reducing surveillance intensity for those who have a low risk of progression reduces the number of biopsies while preserving the benefit of more frequent schedules.